ZTOEF
ZTO Express (Cayman) Inc.
$17.00
0.00%
No data for this timeframe.
Vol
SEC Reports8
Recent Activity
Jun 2, 2026
SEC
ZTO Express filed a routine monthly return with the Hong Kong Stock Exchange for May 2026, reporting no change in issued
6-K — Impact 2/10
May 26, 2026
SEC
ZTO Express filed a Form 6-K disclosing routine share repurchases on the NYSE on May 20-21, 2026, totaling 351,425 ADSs
6-K — Impact 2/10
May 20, 2026
SEC
ZTO Express reported Q1 2026 results with revenue up 22.0% YoY to RMB13.28B and adjusted net income up 5.2% to RMB2.38B,
6-K — Impact 5/10
Analyst Ratings
6Strong Buy
13Buy
1Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
8 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 6 neutral. Avg impact: 3.4/10.
NEUTRAL
6-K
2/10
ZTO Express filed a routine monthly return with the Hong Kong Stock Exchange for May 2026, reporting
Jun 2, 2026
NEUTRAL
6-K
2/10
ZTO Express filed a Form 6-K disclosing routine share repurchases on the NYSE on May 20-21, 2026, to
May 26, 2026
NEUTRAL
6-K
5/10
ZTO Express reported Q1 2026 results with revenue up 22.0% YoY to RMB13.28B and adjusted net income
May 20, 2026
NEUTRAL
6-K
2/10
ZTO Express announced the date of its upcoming board meeting. This is a routine administrative filin
Apr 24, 2026
NEUTRAL
6-K
4/10
ZTO Express filed a 6-K to announce its annual general meeting, proposing the re-election of two dir
Apr 17, 2026
NEUTRAL
6-K
2/10
ZTO Express filed a 6-K to submit its 2025 Annual Report and Sustainability Report to the SEC, as re
Apr 17, 2026
MIXED
20-F
5/10
ZTO Express reported mixed financial results for 2025 with revenue growth but declining profitabilit
Apr 17, 2026
BULLISH
6-K
5/10
ZTO Express repurchased and cancelled 25.6 million Class A ordinary shares in March 2026, reducing i
Apr 8, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 95% buy across 20 analysts — 6 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $14.4B | 22.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $13.8B | 16.1% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $57.4B | 16.9% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $62.5B | 8.9% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 7 | 12 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.